Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats

Neurobiology of Disease

Volumn 64, Issue , 2014, Pages 36-47

  Marin, C ^a,d   Bonastre, M ^a   Mengod, G ^a,d   Cortes R ^a,d   Giralt, A ^b,d   Obeso, J A ^c,d   Schapira, A H ^e  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

6 Hydroxydopamine; Dyskinesias; L dopa; Parkinson's disease; Pramipexole

Indexed keywords

BENSERAZIDE; BROXURIDINE; CYTOCHROME C OXIDASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; GLUTAMATE DECARBOXYLASE 67; LEVODOPA METHYL ESTER; OXIDOPAMINE; PRAMIPEXOLE; PREPRODYNORPHIN; PREPROENKEPHALIN;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXIAL DYSKINESIA; BASAL GANGLION; CELL PROLIFERATION; CIRCLING BEHAVIOR; COMPARATIVE STUDY; CONTROLLED STUDY; DYSKINESIA; EARLY INTERVENTION; GENE EXPRESSION; IMMUNOCOMPETENT CELL; IMMUNOPRECIPITATION; LIMB DYSKINESIA; MALE; MOTOR PERFORMANCE; MOUTH DYSKINESIA; NERVE LESION; NERVOUS SYSTEM DEVELOPMENT; NIGROSTRIATAL LESION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBVENTRICULAR ZONE; THERAPY DELAY;

6-HYDROXYDOPAMINE; DYSKINESIAS; L-DOPA; PARKINSON'S DISEASE; PRAMIPEXOLE;

ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; BENSERAZIDE; BENZOTHIAZOLES; CORPUS STRIATUM; HIPPOCAMPUS; LEVODOPA; MALE; MOTOR ACTIVITY; NEUROGENESIS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D3; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 84891921302     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.12.009     Document Type: Article

References (51)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-induced dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Dis. 2001, 16:448-458.
2. Ahmed M.R., et al. Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by L-DOPA treatment. J. Neurochem. 2008, 104:1622-1636.
3. Aponso P.M., et al. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease. Neuroscience 2008, 151:1142-1153.
4. Baker S.A., et al. Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone. Eur. J. Neurosci. 2004, 20:575-579.
5. Berthet A., et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J. Neurosci. 2009, 29:2835-4829.
6. Bezard E., et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med. 2003, 9:762-767.
7. Blunt S.B., Jenner P., Marsden C.D. Suppressive effect of L-dopa on dopamine cell remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov. Dis. 1993, 8:129-133.
8. Bove J., Perier C. Neurtoxin-based models of Parkinson's disease. Neuroscience 2012, 211:51-76.
9. Cenci M.A., et al. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
10. Clarke C.E., et al. Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?. Mov. Dis. 2011, 26:1187-1193.
11. Datla K.P., Blunt S.B., Dexter D.T. Chronic L-Dopa administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov. Dis. 2001, 16:424-434.
12. Fahn S., et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 2004, 351:2498-2508.
13. Ferger B., et al. Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: a pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. Synapse 2010, 64:533-541.
14. Ferré S., et al. Prime time for G-protein-coupled receptor heteromers as therapeutic targets for CNS disorders: the dopamine D1-D3 receptor heteromer. CNS Neurol. Disord Drug Targets 2010, 9:596-600.
15. Fiorentini C., et al. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol. Pharmacol. 2008, 74:59-69.
16. Freundlieb N., et al. Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J. Neurosci. 2006, 26:2321-2325.
17. Giralt A., et al. BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. Gene Ther. 2010, 17:1294-1308.
18. Gu M., et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 2004, 91:1075-1081.
19. Guigoni C., et al. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S25-S29.
20. Höglinger G.U., et al. Dopamine depletion impairs precursor cell proliferation in Parkinson's disease. Nat. Neurosci. 2004, 7:726-735.
21. Holloway R.G., et al. Pramipexole vs L-Dopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch. Neurol. 2004, 61:1044-1053.
22. Iravani M.M., et al. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp. Neurol. 2008, 212:522-531.
23. Jeon M.Y., Lee W.Y., Kang H.Y., Chung E.J. The effects of L-2-4dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models. Neurol. Res. 2007, 29:289-295.
24. Kemmerer E.S., et al. Treatment effects on nigrostriatal projection integrity in aprtial 6-OHDA lesions: comparison of L-Dopa and pramipexole. Exp. Neurol. 2003, 183:81-86.
25. Larramendy C., et al. Cabergoline and pramipexole fail to modify established dyskinesias in an animal model of parkinsonism. Behav. Brain Res. 2008, 194:44-51.
26. Li C., et al. Neuroprotection of pramipexole in UPS impairment induced in an animal model of Parkinson's disease. Neurochem. Res. 2010, 35:1546-1556.
27. Lipski J., Guatteo E., McKerney J., Yee A., Cucchiaroni M.L., Berreta N., Mercuri N.B. Excitatory action of L-dopa in the substantia nigra pars compacta (SNc)-a contributing factor to neurotoxicity?. Soc. Neurosci. Abstr. 2010, 752:21.
28. Liu B.F., et al. Proliferation of neural precursors in the subventricular zone after chemical lesions of the nigrostriatal pathway in rat brain. Brain Res. 2006, 1106:30-39.
29. Lowry O.H., et al. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
30. Marcellino D., et al. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J. Biol. Chem. 2008, 283:26016-26025.
31. Marin C., et al. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp. Neurol. 2006, 197:269-274.
32. Marin C., et al. Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes. Neurobiol. Dis. 2008, 32:340-348.
33. Marin C., et al. Effects of early vs late initiation of L-Dopa treatment in hemiparkinsonian rats. Eur. J. Neurosci. 2009, 30:823-832.
34. Nielsen K.M., Soghomonian J.J. Dual effects of intermittent or continuous L-DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6-OHDA lesion. Synapse 2003, 49:246-260.
35. Obeso J.A., Schapira A.H. Compensatory mechanisms in Parkinson's disease. Mov. Disord. 2009, 24:153-154.
36. Obeso J.A., et al. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000, 55(11 Suppl. 4):S13-S20.
37. Oizumi H., et al. Alteration in the differentiation-related molecular expression in the subventricular zone in a mouse model of Parkinson's disease. Neurosci. Res. 2008, 60:15-21.
38. Parkinson Study Group Pramipexole versus L-Dopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 2000, 284:1931-1938.
39. Parkinson Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. Arch. Neurol. 2004, 61:561-566.
40. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, New York.
41. Piercey M.F. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin. Neuropharmacol. 1998, 21:141-151.
42. Rascol O., et al. A double, blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS score, and non-motor outcomes. Lancet Neurol. 2011, 10:415-423.
43. Schallert T., et al. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
44. Schapira A.H. The importance of LRRK2 mutations in Parkinson's disease. Arch. Neurol. 2006, 63:1225-1228.
45. Schapira A.H., Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann. Neurol. 2006, 59:559-562.
46. Schapira A.H., Olanow C.W. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann. Neurol. 2008, 65:S47-S55. (Suppl.).
47. Schapira A.H., et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomized delayed-start trial. Lancet Neurol. 2013, 12:747-755.
48. Tayarani-Binazir K.A., et al. Pramipexole combined with L-Dopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Mov. Disord. 2010, 25:377-384.
49. Winner B., et al. Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Exp. Neurol. 2009, 219:543-552.
50. Zhang R.L., et al. Proliferation and differentiation of progenitor cells in the cortex and the subventricular zone in the adult rat after local cerebral ischemia. Neuroscience 2001, 105:33-41.
51. Zou L., et al. Neuroprotection by pramipexole against dopamine-and levodopa-induced cytotoxicity. Life Sci. 1999, 64:1275-1285.